#United States #Spring House #oncology #Immunology #Third Arc Bio

Third Arc Bio Secures $52 Million to Expand its Cancer and Immune Therapy Portfolio

In a groundbreaking development, Third Arc Bio Inc., a biotech firm currently in the clinical stage, has successfully closed a $52 million extension to their Series A funding. This financial boost is expected to accelerate the company's innovative work in the fields of oncology and immunology. The funding comes alongside a previously announced $165 million Series A, significantly reinforcing Third Arc Bio's capabilities in developing multifunctional antibodies targeted for various medical indications.

New Investors and Leadership

The latest round of investment was spearheaded by the renowned venture capital firm Andreessen Horowitz (a16z), which joined the ranks of existing investors including Omega Funds and several others. Notably, Jorge Conde, a General Partner at a16z, will now join the Board of Directors at Third Arc Bio. This addition is anticipated to provide further strategic support as Third Arc Bio continues to validate its approach towards delivering transformative therapies for patients with serious health conditions.

Jorge Conde emphasized the significance of Third Arc’s vision, stating, "Third Arc represents a shift toward more precise immune modulation, moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease." He remarked that the company's innovative platforms along with their proficient team can potentially lead to highly effective and safe biologics for patients suffering from cancer and immune-mediated diseases.

Company Vision and Pipeline

Since its inception in 2022 with seed capital from Omega Funds, Third Arc Bio has assembled a talented team recognized for their expertise in drug discovery and development. They are currently focusing on their lead asset, ARC101, which is a bispecific T-cell engager targeting CLDN6 and is currently undergoing a Phase 1 trial for patients with advanced solid tumors.

Peter F. Lebowitz, the Chief Executive Officer of Third Arc Bio, expressed enthusiasm for the recent funding, stating, "This financing allows us to maintain momentum across our expanding oncology portfolio while rapidly advancing our next-generation inflammation assets into first-in-human studies." He highlighted the importance of a parallel-tracking approach to validate their platforms efficiently and generate proof-of-concept data swiftly.

Innovative Platforms

One of the cornerstones of Third Arc Bio's approach is its ARCTag (Tethered Agonist) Platform. This groundbreaking technology employs multispecific antibodies, allowing for targeted immune modulation right at the disease sites. This represents a considerable leap over traditional systemic therapies, promising enhanced efficacy and a greater therapeutic index for patients.

Through this innovative strategy, Third Arc aims to provide treatment solutions to patients who have significant unmet medical needs, ultimately reshaping the landscape of oncology and inflammation therapies.

About Third Arc Bio

Third Arc Bio is dedicated to developing multifunctional antibodies that can precisely engage T cells and modulate the immune response. Their lead program, ARC101, is under evaluation in clinical trials, focusing on patients with solid tumors expressing CLDN6. By leveraging cutting-edge technologies, the company hopes to establish itself as a leader in the field, offering next-generation, high-value therapeutics.

For more information on Third Arc Bio and its innovative research, please visit www.thirdarcbio.com.